Hadid Bana, Kodza Arif, Suresh Sumatha Channapatna, Feoktistov Aleksander
State University of New York Downstate Health Sciences University, College of Medicine, Brooklyn, NY, USA.
State University of New York Downstate Health Sciences University, Department of Internal Medicine, Brooklyn, NY, USA.
Mediterr J Rheumatol. 2023 Aug 11;34(4):537-543. doi: 10.31138/mjr.110823.raa. eCollection 2023 Dec.
Acquired amegakaryocytic thrombocytopenia (AAMT) is a rare cause of thrombocytopenia seen in systemic lupus erythematosus (SLE) that is frequently misdiagnosed as immune thrombocytopenic purpura (ITP). Often patients do not respond to standard ITP treatment. Prompt bone marrow biopsy and further workup should ensue as it is a diagnosis of exclusion. While no standard guidelines exist, the mainstay of treatment is immunosuppressive therapy. Some cases are refractory and should have a follow-up biopsy, typically showing worsening disease. The exact pathogenesis is unclear; multiple mechanisms may be involved, suggesting AAMT may be a syndrome of various aetiologies rather than a distinct pathology. A common complication is aplastic anaemia, and the patient may need a haematopoietic stem cell transplant (HSCT). We present a young man with severe refractory AAMT in the setting of SLE that progressed to aplastic anaemia and required an HSCT. We then discuss and interpret the literature on AAMT.
获得性无巨核细胞性血小板减少症(AAMT)是系统性红斑狼疮(SLE)中血小板减少的罕见原因,常被误诊为免疫性血小板减少性紫癜(ITP)。患者通常对标准的ITP治疗无反应。由于这是一种排除性诊断,应立即进行骨髓活检及进一步检查。虽然不存在标准指南,但治疗的主要方法是免疫抑制治疗。一些病例具有难治性,应进行随访活检,通常显示病情恶化。确切的发病机制尚不清楚;可能涉及多种机制,提示AAMT可能是一种病因各异的综合征,而非一种独特的病理状态。一种常见的并发症是再生障碍性贫血,患者可能需要进行造血干细胞移植(HSCT)。我们报告了一名患有严重难治性AAMT的年轻男性,该疾病发生于SLE背景下,进展为再生障碍性贫血并需要进行HSCT。然后我们讨论并解读了关于AAMT的文献。